Vol 12, No 3 (2016)
Case report
Published online: 2016-08-31
Posterior reversible encephalopathy syndrome (PRES) induced by intrathecal methotrexate administration in a patient with acute lymphoblastic leukaemia
Oncol Clin Pract 2016;12(3):102-104.
Abstract
A patient with B-cell precursor acute lymphoblastic leukaemia was diagnosed with posterior reversible encephalopathy syndrome (PRES) after an intrathecal administration of methotrexate during induction chemotherapy. PRES presented with headache, epilepsy, unconsciousness, blurred vision, hypertension, and vomiting. Also, characteristic lesions of the central nervous system were revealed by magnetic resonance imaging of the head, especially in the white matter of the posterior lobes.
Keywords: chemotherapychildhoodepilepsyhypertensionmagnetic resonance imaging
References
- Hyo-Jeong L. Posterior Reversible Encephalopathy Syndrome. Appl Radiol. 2007; 36: 42–3.
- Fugate JE, Claassen DO, Cloft HJ, et al. Posterior reversible encephalopathy syndrome: associated clinical and radiologic findings. Mayo Clin Proc. 2010; 85(5): 427–432.
- Legriel S, Pico F, Azoulay E. Understanding Posterior Reversible Encephalopathy Syndrome. Annual Update in Intensive Care and Emergency Medicine 2011. 2011; XV(1): 631–653.
- The International BFM Study Group. A Randomized Trial of the I-BFM-SG for the Managment of Childhood non-B Acute Lymphoblastic Leukemia. ALLIC-BFM 2009.
- Aradillas E, Arora R, Gasperino J. Methotrexate-induced posterior reversible encephalopathy syndrome. J Clin Pharm Ther. 2011; 36(4): 529–536.